Ventricular pacing – Electromechanical consequences and valvular function

Elisa Ebrille a,b, Christopher V. DeSimone a, Vaibhav R. Vaidya a, Anwar A. Chahal a,c, Vuyisile T. Nkomo a, Samuel J. Asirvatham a,d,*

a Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
b Division of Cardiology, Department of Medical Sciences, Città della Salute e della Scienza, University of Turin, Turin, Italy
c Clinical and Translational Science, Mayo Graduate School, Rochester, MN, USA
d Department of Pediatrics and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA

Article history:
Available online 4 March 2016

Keywords:
Biventricular pacing
Resynchronization
Right ventricular pacing
Atrioventricular septum
Dysynchrony
Valvular regurgitation

Abstract

Although great strides have been made in the areas of ventricular pacing, it is still appreciated that dyssynchrony can be malignant, and that appropriately placed pacing leads may ameliorate mechanical dyssynchrony. However, the unknowns at present include:

1. The mechanisms by which ventricular pacing itself can induce dyssynchrony;
2. Whether or not various pacing locations can decrease the deleterious effects caused by ventricular pacing;
3. The impact of novel methods of pacing, such as atrioventricular septal, lead-less, and far-field surface stimulation;
4. The utility of ECG and echocardiography in predicting response to therapy and/or development of dyssynchrony in the setting of cardiac resynchronization therapy (CRT) lead placement;
5. The impact of ventricular pacing-induced dyssynchrony on valvular function, and how lead position correlates to potential improvement.

This review examines the existing literature to put these issues into context, to provide a basis for understanding how electrical, mechanical, and functional aspects of the heart can be distorted with ventricular pacing. We highlight the central role of the mitral valve and its function as it relates to pacing strategies, especially in the setting of CRT. We also provide future directions for improved pacing modalities via alternative pacing sites and speculate over mechanisms on how lead position may affect the critical function of the mitral valve and thus overall efficacy of CRT.

Copyright © 2016, Indian Heart Rhythm Society. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Cardiac pacing is an established and effective treatment for sinus node disease and atrioventricular block [1,2]. The right ventricular (RV) apex has been the standard pacing site since the development of implantable pacemaker technology because of the relative ease of access, lead stability, and the presumed safety of the right-sided circulation compared to the left (fewer fatal thromboembolic sequelae) [3]. However, several studies have shown that RV apical pacing creates electrical dysynchrony and has detrimental effects on cardiac structure, function, and can lead to development of atrial fibrillation, valvular regurgitation and severe congestive heart failure [4–12].

Cardiac resynchronization device therapy (CRT) has shown to improve morbidity and mortality in patients with congestive heart failure [13–16], and recent trial data has expanded the indications for its use [17–24]. CRT is thought to improve atrioventricular, intraventricular and interventricular dysynchrony through the simultaneous activation of the RV and the left ventricle (LV) [1]. The Achilles heel of CRT is the substantial number (up to 1/3) of patients that do not benefit, termed “non-responders” [25].

The utility of baseline electrocardiogram (ECG) in detecting dysynchrony, together with multiple imaging and device based studies have attempted to identify criteria for improved patient selection, but no single validated and reliable marker has been identified [26–28]. Alternative pacing locations and the impact of novel pacing methods such as atrioventricular, leadless and far-field stimulation from the surface of the heart seem to decrease the deleterious dysynchronous effects of pacing [29–31].

Finally, pacing-induced dysynchrony affects valvular function as well. Tricuspid and mitral regurgitation occur or worsen if abnormal ventricular mechanic is present [32–34], and appropriately placed pacing leads can actually improve valvular function through various mechanisms [35–37].

We review the current knowledge on RV pacing and CRT, provide an overview on pacing modalities and mechanisms of dysynchrony-induced ventricular dysfunction and valvular regurgitation, ways to improve CRT through innovation, and how this can be translated to tangible therapeutic options that are safe, effective, and mechanistically sound.

Ventricular pacing effects on the electrical, mechanical, and structural functions of the heart

Part 1. Electrical activation of the heart, pathophysiology of pacing and why mechanical dysfunction occurs from ventricular pacing

During normal sinus rhythm, electrical activation occurs through the cardiac conduction system. The depolarization wave front spreads sequentially from the atria, to the atrioventricular node, through the His-Purkinje system, resulting in almost simultaneous activation of both ventricles. The result of this is manifesting on ECG as a narrow QRS complex. In contrast, RV apical pacing causes the earliest depolarization to occur at the segment of the RV apex, followed by slow, cell-to-cell spread of the activation wavefront, with latest depolarization at the inferoposterior base of the LV [38]. This produces a wide QRS and a left superior axis on ECG.

RV pacing produces an iatrogenic form of left bundle branch block (LBBB). Native LBBB can cause hemodynamic deterioration due to ventricular dysynchrony, mainly in patients with heart failure. However, LBBB induced by RV apical pacing seems to lead to worse outcomes when compared to native LBBB, increasing ventricular dysynchrony [39–41]. The latest LV mechanical activation during RV apical pacing, indeed, is different from that during native LBBB, being more delayed at the baso-lateral LV wall [42].

The abnormal electrical and mechanical activation caused by RV apical pacing reduces stroke volume and causes a right-shift of the left ventricular end-systolic pressure–volume relationship. In addition to hemodynamic consequences, RV apical pacing can worsen coronary blood flow, regional myocardial fiber shortening, and any pre-existing mechanical dysynchrony [12,43,44]. Moreover, regional patterns of ventricular activation are also altered in a complex manner [45]. Early activation of the RV apex results in vigorous RV apical shortening. Early apical shortening leads to stretching of remote ventricular regions, such as the LV free wall, and subsequent stronger contraction of these regions is needed compared to the local RV apical regions. Another important mechanical effect of RV apical pacing is abrupt posterior motion of the interventricular...
This occurs due to earlier development of pressure in the RV compared to the LV and results in a decrease in left ventricular end diastolic volume, and consequently reduction in the cardiac output.

Several studies have shown superiority of CRT compared to standard RV apical pacing in terms of survival and freedom from heart failure both in patients with preserved and reduced ejection fraction [15–23]. Typically, in CRT devices three pacing leads are placed: one in the right atrium, a second one on the endocardial aspect of the RV apex, and a third lead is placed transvenously through the coronary sinus to pace the epicardial wall of the LV. During CRT pacing, the electrical activation of the myocardium occurs again through a cell-to-cell mechanism, but the simultaneous pacing from the RV and the LV leads to a decrease in the electrical delay, increases coordinated contraction between the different walls of the heart, and results in a narrower QRS complex on the surface ECG (Figs. 1 and 2). Simultaneously stimulation of the RV and LV, therefore, should restore a coordinated pumping action. Electrical resynchronization between the RV and LV should eliminate both the LBBB-induced mechanical dyssynchrony due to a preexisting cardiomyopathy and the LBBB-induced dyssynchrony caused by RV apical pacing alone [47]. However, as previously stated, RV apical pacing increases ventricular dyssynchrony compared with intrinsic LBBB. For this reason, if LV pacing alone is performed with such an atrio-ventricular delay able to ensure intrinsic activation of the heart via the right bundle branch (RBB), the fusion of these two depolarization wave fronts should be more effective than biventricular pacing [48–50]. Varma et al. [49] used electrocardiographic imaging to compare RV activation during intrinsic conduction and during pacing in patients with heart failure. Patients with normal RBB-mediated depolarization showed normal RV free wall activation, whereas they developed activation delay when RV pacing was switched on, alone or in a biventricular fashion. These data again suggest that merging of LV paced and intrinsic RBB wave fronts could be beneficial. Moreover, programmability of the inter-ventricular interval between RV and LV stimulation may further improve hemodynamics [51].

Baseline QRS duration is one of the most commonly used parameters in patient selection for CRT, but remains a weak criterion to predict response [52–54]. Current guidelines [1,2] suggest CRT implant in patients with heart failure and QRS duration >150 ms, or with an additional indicator of supposed good response, such as LBBB morphology, if the QRS is 120–150 ms. Right bundle branch block or aspecific intraventricular conduction delay seem to predict no positive effect or even be responsible for negative response to CRT [27]. However, several studies have shown that neither QRS duration at implant nor shortening of QRS after implant necessarily predicts clinical benefit from CRT [28,55–57]. Recently, a study from Del-Carpio Munoz et al. [58] showed that a noninvasive method of determining LV activation delay, by analyzing the time to intrinscoid deflection onset on surface ECG, represents a promising alternative to QRS duration to predict CRT.
response. Moreover, a subanalysis of MADIT-CRT trial showed a survival benefit of CRT devices in patients with LBBB compared to the group of patients assigned to defibrillators alone, independently to QRS duration [59]. On the other hand, a recent trial showed that in patients with heart failure and with QRS duration < 130 ms, CRT didn’t reduce the rate of death or hospitalization and might even increase mortality, even if mechanical dyssynchrony was present [60].

Electrical dyssynchrony and mechanical dyssynchrony could be two different entities, as explained by the concept of “electromechanical dissociation.” [52] Electromechanical coupling interval can significantly be different on a patient-to-patient basis, and not strictly related to the widening of the QRS complex. Electromechanical delay, defined as the time between the regional electrical depolarization and the onset of myocardial fiber contraction, or mechanical activation, is responsible for additional electromechanical dys-synchrony. The mechanical delay between early and late-activated myocardial segments exceeds the delay in electrical activation during LBBB and during pacing-induced dyssynchrony [61,62], aggravating mechanical relative to electrical dyssynchrony.

Moreover, latency from pacing stimulus to the onset of the earliest QRS further impacts on optimal delivery of CRT [63]. Latency has shown to be more prevalent during LV pacing from the epicardial veins than during RV endocardial pacing, possibly due to the longer distance from the subendocardial His-Purkinje system, interposed epicardial fat, venous tissue and slow impulse propagation in scarring and diseased myocardium [64].

It has been thought that ischemic patients have been less responsive to CRT, propagating studies to assess for amount and location of scar to CRT response [65,66]. The amount of scar and its location in the posterolateral segment of the LV appear to be a predictor of CRT non-response [67]. Delayed-enhancement magnetic resonance imaging is a useful tool to predict clinical response to CRT [68–70]. Even if studies showed that scar does not preclude myocardial capture, pacing regions of the myocardium characterized by scar tissue may not be translated into effective mechanical contraction, because both absence of sufficient viable tissue to be recruited with CRT and also because of inadequate synchronization due to scar presence [71]. Moreover, the higher percentage of CRT “non-responders” among patients with ischemic heart disease seems to be ascribed more likely to conduction abnormalities and electrical substrate issues rather than cardiomyopathy etiology itself.

Non-response to CRT appears to be associated to a myriad of electo-mechanical events. Dendy et al. [72] found anodal stimulation as an additional cause of poor response to CRT. Anodal stimulation is defined as capture at the pacing anode rather than cathode and is sometimes unrecognized peripherally [73]. In patients with CRT, pacing from the LV tip or ring to the coil or ring of the RV lead is often used due to lower pacing thresholds. PACing configuration of LV to RV can lead to clinically significant anodal stimulation resulting in RV capture during attempted LV pacing. If the benefit from CRT occurs through improvement in LV late depolarization, CRT with anodal stimulation essentially results in RV pacing alone, leading to persistent interventricular and intraventricular conduction delay to the LV lateral wall. However, Lloyd et al., using left ventricular outflow tract velocity time integral as a marker of response, showed anodal pacing to markedly improve this parameter compared to cathodal pacing in 36/37 recordings [74]. Additionally, controversy exists over whether anodal pacing is beneficial or harmful. This is partially driven by the complexities in defining what an adequate response to CRT is. For example, it can be symptomatic improvement, or a marker of mechanical improvement depending on the fact that an invasive catheter based assessment such as dP/dt or an echocardiographic based assessment such as ejection fraction, dP/dt, Doppler is used. Both animal and clinical studies have demonstrated improved mechanical performance by anodal stimulation, and this is thought to be due to activation of larger volume of myocardium, increased amount of sodium available, and more rapid conduction velocity [75,76].

Part 3. Valvular Regurgitation

The first known association of tricuspid regurgitation (TR) and device implantation was described in 1980 [77]. Since then, several case reports and observational studies have supported this association. Both new onset TR and worsening TR can occur by the mechanical effects of lead implantation or electrical dyssynchrony, which can occur early or late after device implantation [78–81]. Conversely, some small studies have suggested an improvement of TR after pacing [82]. The prevalence of TR is 25%–50% in patients with pacemaker vs no pacemaker [83,84]. The clinical presentation of TR is highly variable, from asymptomatic and incidentally detected on echocardiography, to the more severe clinical presentation of right-sided heart failure. The mechanism of TR after device implantation includes valve tethering, inadequate leaflet coaptation due to the physical presence of lead, lead adherence due to fibrosis and scar formation, lead entrapment in the subvalvular apparatus, valve perforation, valve laceration, and annular dilatation [77,85,86].

Long-term RV apical pacing is also responsible for causing mitral regurgitation (MR) due to LV dysynchrony. A study from Alizadeh et al. shows how degree of MR can worsen during follow-up in patients with permanent apical RV pacing [32]. There are a few reported cases of acute severe MR as an immediate perioperative complication of pacemaker inser- tion, leading to acute hemodynamic deterioration, even in patients with preserved LV ejection fraction [87–91]. The mechanism of this includes mitral annular dilatation and abnormal leaflet coaptation perhaps due to the abnormal LV activation sequence [92,93]. It is likely that the inversion of the ventricular activation sequence with RV apical pacing is associated with a delayed reduction of both mitral annulus size and regurgitation orifice size, and this enhances MR severity [35]. Furthermore, if alteration in timing of papillary muscle contraction is corrected with a different lead location in the RV (such as the right ventricular outflow tract) or with a left-sided pacing system, degree of MR has been shown to improve [94].

Moreover, the presence of MR in patients with heart failure, before device implantation, has been showed to be an independent predictor of worsened survival [95,96]. This type of
MR, usually referred as “functional” or “secondary,” is due to dilatation of the left ventricle. Three main mechanisms are involved in secondary MR: 1) mitral annular dilatation, 2) decreased LV global systolic function, responsible for slow rise of intraventricular pressure and slow closure of mitral leaflets, 3) increased LV sphericity with subsequent displacement and malposition of the papillary muscles, leading to decreased longitudinal systolic function and increased mitral valve tethering forces [33,34]. Recently, Topilsky et al. [97] used 3D transthoracic echocardiography to show the complex interaction between mitral valve dynamics and ventricular contraction. The loss of annular contraction across the inter-commisural axis, usually responsible for early-systolic mitral competence, and the change in papillary muscle dynamics were linked to the severity of MR. Moreover, the presence of LBBB itself in patients with dilated cardiomyopathy, increasing LV isovolumic contraction and relaxation times, is responsible for worsening MR duration [98].

Cardiac resynchronization therapy, reducing electrical and mechanical dyssynchrony and leading to a final increased efficiency of LV contraction, has shown to have beneficial effects on ‘secondary’ MR [35–37,94,99–101]. Kanzaki et al. [36], utilized echo-cardiographic Doppler and strain images before and immediately after CRT implant, and showed a significant reduction in the coordinated timing of mechanical activation of papillary muscle insertion sites and in the severity of MR after CRT implant (p < 0.001 for both comparisons). Agricola et al. [34], showed how CRT may reduce the delay in electrical activation and subsequent mechanical activity of the papillary muscle, improving contraction coordination. They stated that, with enlarged spheric ventricle, both papillary muscles are posteriorly displaced. The anterolateral papillary muscle shifts far from interventricular septum and more towards the posterior/posterolateral veins, where the left-sided CRT lead is usually implanted. In this way, the stimulation of the LV free wall can counterbalance the delay in electrical activation of the anterior papillary muscle caused by LBBB and improve muscle coordination. Matsumoto et al., [102] instead, showed an asymmetrical displacement of papillary muscles in patients with dilated cardiomyopathy, with the anterolateral papillary muscle being more posteriorly located than the posteromedial one. The restoration of the anterolateral papillary muscle position after CRT implant was one of the independent predictors of MR reduction at 6 month followup.

Moreover, thanks to a more coordinated and earlier mechanical contraction of the basal segments of the LV compared to the more apical ones, an increase in mitral annular systolic function may be achieved, leading to reduction of MR [94,99]. Earlier mitral annular contraction was hypothesized to be the responsible mechanism of a dramatic symptom improvement in a patient with RV pacing and heart failure who subsequently underwent an upgrading to a biventricular device with the LV lead being positioned in a very basal-lateral position. DeSimone et al., [103] indeed, observed an acute and significant reduction in MR and LV size dimensions with proper LV lead placement causing mitral annular pre-excitation. Ypenburg et al. [35] reported findings consistent with this by showing an acute improvement in MR after CRT, as well as during follow-up. In addition to the 43% acute improvement, the authors demonstrated a 20% reduction of late MR 6 months after CRT. Moreover, the beneficial effects of CRT are maintained until the therapy itself is interrupted, possibly suggesting a dynamic influence on mitral valve activation kinetics. Following CRT withdrawal, acute loss of synchronization is responsible for acute MR recurrence and worsening in mitral functional parameters [94].

Future directions

Understanding the mechanism of how mitral valve mechanics and other dyssynchrony parameters are improved with biventricular pacing will provide critical data necessary to improve number of CRT response in patients with heart failure. The location where transvenous LV leads are placed via the coronary sinus has been considered of utmost importance for CRT optimal response [104]. Meanwhile, stimulation sites alternative to RV apical pacing have been extensively studied to simulate a more physiologic electrical activation of the heart, to reduce ventricular dysynchrony and to obtain more favorable hemodynamics. Few studies regarding non-traditional pacing sites in the right ventricle, such as the RV septum or the RV outflow tract, and His-bundle pacing have been reported in the literature (Fig. 4) [84,105–111].

The RV outflow tract has been considered primarily because placement of leads is technically easier compared to most other locations. The reason for interest in this region is that activation should result in electrical propagation from base to apex with a QRS morphology more similar to the standard QRS derived from normal cardiac conduction system, even if the duration of the QRS itself may not be significantly improved [112–115]. RV mid-septal pacing has also been used as an alternative to RV apical pacing [116]. Even if lead implantation in the inter-ventricular septum has showed to be feasible, safe, and associated with less ventricular dys-synchrony compared to standard apical pacing, no overt clinical benefits have been found [117–119]. However, both of these alternative sites still require crossing the tricuspid valve, with the potential risk of TR.

His-bundle pacing was first demonstrated in 1967 in dogs [120]. However, in this location, stable capture is difficult to obtain and higher thresholds and longer implant times are often necessary [121,122]. The issues with His-bundle pacing may be partially attenuated with parahisian pacing, in which both the His and the myocardium of the high interventricular septum are stimulated together [123]. However, parahisian pacing produces a base-to-apex activation pattern that is completely different from the true His-bundle capture, characterized by the earliest site of ventricular activation at the exit site of the right and left bundle.

More novel approaches include lead-less pacemakers such as the ‘Nanostim’ (St. Jude Medical Inc., Minneapolis, MN, USA) [124] and the ‘Micra™ Transcatheter Pacing System’ (Medtronic Inc., Minneapolis, MN, USA) which was recently implanted in man (NCT02004873, www.clinicaltrials.gov). Other lead-less pacing systems use ultrasound-based technology and have been tested clinically for short-term use in LV pacing [31]. A comparison of lead-less RV apical pacing with
transvenous pacing may provide interesting insights into the mechanisms of both MR and TR: how much is mechanically caused by the leads vs. electrical dyssynchrony from the RV apical pacing.

Concerning the use of CRT devices, with advances in coronary sinus cannulation and dedicated LV technology, the transvenous approach through the coronary sinus itself has become the standard technique, even if limitations such as technical challenges in finding electrically suitable sites still exist. Multisite pacing, mimicking the native conduction system activation [125], or multipoint pacing [126], using multiple electrodes on one LV lead, could optimize synchronous

Fig. 3 – Panel A: Mechanisms of mitral regurgitation in patients with heart failure. Panel B: Beneficial effects of CRT on ‘secondary’ mitral regurgitation.
myocardial activation. However, the ideal CRT system would allow synchronous ventricular contraction without the need to enter the coronary sinus or cross the tricuspid valve. Based on the anatomical consideration that the tricuspid valve is more apical than the mitral valve and the atrioventricular septum separates, at a certain location, the right atrium and the LV basal septum (Fig. 5), our group recently developed a specially built intra-myocardial lead to pace the ventricular myocardium from the atrioventricular septum itself [29,127]. The intra-myocardial lead, together with this new form of synchronous pacing, could offer important advantages either in patients without heart failure who require ventricular pacing or in patients with heart failure who are candidates for resynchronization therapy. Undoubtedly, larger studies with long-term follow-up are needed to evaluate safety, stability and durability of the novel lead and the enhanced potential benefit of the atrioventricular septum location for pacing.

**Fig. 4** — Illustration showing alternative sites for RV pacing indicated by stars. LAF = Left Anterior Fascicle; LBB = Left Bundle Branch; LPF = Left Posterior Fascicle; RBB = Right Bundle Branch; RVOT = Right Ventricular Outflow Tract.

**Fig. 5** — Gross anatomy and histological images showing the atrio-ventricular septum region. The tricuspid valve is more apical than the mitral valve and the atrio-ventricular septum separates, at a certain location, the right atrium and the LV basal septum. AVS = Atrio-ventricular Septum; MV = Mitral Valve; TV = Tricuspid Valve.

**Conclusions**

The field of cardiac pacing is faced with a great task to improve the utility of ventricular pacing while mitigating potential for undesired effects on heart structure and function. Further research to clarify the relationship of the critical role that the position and type of pacing leads have on proper mitral valvular function is of paramount importance. Without question, further innovative strategies will need to be
employed and will be a work in progress as more pacing data, especially with the increase in CRT use, become available in the literature.

REFERENCES

[1] Epstein AE, DiMarco JP, Ellenbogen KA, Estes 3rd NA, Freedman RA, Gettes LS, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2013;61:6–75.

[2] Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Dev Collab Eur Heart Rhythm Assoc (EHRA) Eur 2013;15:1070–118.

[3] Bongiorni MG, Proclerem A, Dobreanu D, Marinisks G, Pison I, Blomstrom-Lundqvist C. Preferred tools and techniques for implantation of cardiac electronic devices in Europe: results of the European Heart Rhythm Association survey. Euro 2013;15:1664–8.

[4] Rosenqvist M, Isakz K, Botvinick EH, Dawe MW, Cockrell J, Abbott JA, et al. Relative importance of activation sequence compared to atrioventricular synchrony in left ventricular function. Am J Cardiol 1991;67:148–56.

[5] Tantengco MV, Thomas RL, Karpawich PP. Left ventricular dysfunction after long-term right ventricular apical pacing in the young. J Am Coll Cardiol 2001;37:2093–100.

[6] Lin G, Nishimura RA, Connolly MG, Dearani JA, Sundt 3rd TM, Hayes DL. Severe symptomatic tricuspid valve regurgitation due to permanent pacemaker or implantable cardioverter-defibrillator leads. J Am Coll Cardiol 2005;45:1672–5.

[7] Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. Jama 2002;288:3115–23.

[8] Connolly SJ, Kerr CR, Gent M, Roberts RS, Yusuf S, Gills AM, et al. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian trial of physiologic pacing investigators. N Engl J Med 2000;342:1385–91.

[9] Kristensen L, Nielsen JC, Mortensen PT, Pedersen OL, Pedersen AK, Andersen HR. Incidence of atrial fibrillation and thrombemboim in a randomised trial of atrial versus dual chamber pacing in 177 patients with sick sinus syndrome. Heart 2004;90:661–6.

[10] Nielsen JC, Kristensen L, Andersen HR, Mortensen PT, Pedersen OL, Pedersen AK. A randomized comparison of atrial and dual-chamber pacing in 177 consecutive patients with sick sinus syndrome: echocardiographic and clinical outcome. J Am Coll Cardiol 2003;42:614–20.

[11] Lieberman R, Padeletti L, Schneider J, Jackson K, Michelucci A, Colella A, et al. Ventricular pacing lead location alters systemic hemodynamics and left ventricular function in patients with and without reduced ejection fraction. J Am Coll Cardiol 2006;48:1634–41.

[12] Healey JS, Toff WD, Lamas GA, Andersen HR, Thorpe KE, Ellenbogen KA, et al. Cardiovascular outcomes with atrial-based pacing compared with ventricular pacing: meta-analysis of randomized trials, using individual patient data. Circulation 2006;114:11–7.

[13] Daubert JC, Saxon L, Adamson PB, Auricchio A, Berger RD, Beshai JF, et al. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace 2012;14:1236–86.

[14] Prinzen FW, Vernooij K, Auricchio A. Cardiac resynchronization therapy: state-of-the-art of current applications, guidelines, ongoing trials, and areas of controversy. Circulation 2013;128:2407–18.

[15] Linde C, Abraham WT, Gold MR, St John Sutton M, Chio S, Daubert C. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008;52:1834–43.

[16] Moss AJ, Hall JW, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329–38.

[17] Doshi RN, Daoud GC, Fellows C, Turk K, Duran A, Hamdan MH, et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 2005;16:1160–5.

[18] Kindermann M, Hennen B, Jung J, Geisel J, Bohm M, Frohlig G. Biventricular versus conventional right ventricular stimulation for patients with standard pacing indication and left ventricular dysfunction: the Homburg Biventricular Pacing Evaluation (HOBIPACE). J Am Coll Cardiol 2006;47:1927–37.

[19] Yu CM, Chan JY, Zhang Q, Omar R, Yip GW, Hussien A, et al. Biventricular pacing in patients with bradycardia and normal ejection fraction. N Engl J Med 2009;361:2123–34.

[20] Brignole M, Botto G, Mont I, Iacopino S, De Marchi G, Oddone D, et al. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J 2011;32:2420–9.

[21] Chan JY, Fang F, Zhang Q, Fung JW, Razali O, Azlan H, et al. Biventricular pacing is superior to right ventricular pacing in bradycardia patients with preserved systolic function: 2-year results of the PACE trial. Eur Heart J 2011;32:2533–40.

[22] Albertsen AE, Mortensen PT, Jensen HK, Poulsen SH, Egebild H, Nielsen JC. Adverse effect of right ventricular pacing prevented by biventricular pacing during long-term follow-up: a randomized comparison. Eur J Echocardiogr 2011;12:767–72.

[23] Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010;363:2385–9.

[24] Curtis AB, Worely SJ, Adamson PB, Chung ES, Niazi I, Sherfese I, et al. Biventricular pacing for atriocavitary block and systolic dysfunction. N Engl J Med 2013;368:1585–93.

[25] Russo AM, Stainback RF, Bailey SR, Epstein AE, Heidenreich PA, Jessup M, et al. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Heart Rhythm 2013;10:e11–58.
Chung ES, Leon AR, Tavazzi L, Sun JP, Nihoyannopoulos P, Merlino J, et al. Results of the predictors of response to CRT (PROSPECT) trial. Circulation 2008;117:2608–16.

Zareba W, Klein H, Cygankiewicz I, Hall WJ, McNitt S, Brown M, et al. Effectiveness of cardiac resynchronization therapy by QRS morphology in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT). Circulation 2011;123:1061–72.

Ghio S, Constantin C, Klersy C, Serio A, Fontana A, Campana C, et al. Interventricular and intraventricular dyssynchrony are common in heart failure patients, regardless of QRS duration. Eur Heart J 2004;25:571–8.

Konecny T, DeSimone CV, Friedman PA, Bruce C, Asirvatham SJ. Synchronous intra-myocardial ventricular pacing without crossing the tricuspid valve or entering the coronary sinus. Cardiovasc Revasc Med 2013;14:137–8.

Reddy VY, Knops RE, Sperzel J, Miller MA, Petru J, Simon J, et al. Permanent leadless cardiac pacing: results of the leadless trial. Circulation 2014;129:1466–71.

Auricchio A, Delnopy PF, Regoli F, Seifert M, Markou T, Butter C. First-in-man implantation of leadless ultrasound-based cardiac stimulation pacing system: novel endocardial left ventricular resynchronization therapy in heart failure patients. Europace 2013;15:1191–7.

Alizadeh A, Sanati HR, Haji-Karimi M, Yazdi AH, Rad MA, Haghjoo M, et al. Induction and aggravation of atrioventricular valve regurgitation in the course of chronic right ventricular apical pacing. Europace 2011;13:1587–90.

Vinereanu D. Mitral regurgitation and cardiac resynchronization therapy. Echocardiography 2008;25:1155–66.

Agricola E, Galdieri M, Mele D, Ansalone G, Dini FL, Di Salvo G, et al. Mechanical dyssynchrony and functional mitral regurgitation: pathophysiology and clinical implications. J Cardiovasc Med Hagerst 2008;9:461–9.

Ypenburg C, Lancellotti P, Tops LF, Boersma E, Bleeker GB, Holman ER, et al. Mechanism of improvement in mitral regurgitation after cardiac resynchronization therapy. Eur Heart J 2008;29:757–65.

Kanzaki H, Bazar R, Schwartzman D, Dohi K, Sade LE, Gorcsan 3rd J. A mechanism for immediate reduction in mitral regurgitation after cardiac resynchronization therapy: insights from mechanical activation strain mapping. J Am Coll Cardiol 2004;44:1619–25.

Liang YJ, Zhang Q, Fung JW, Chan JY, Yip GW, Lam YY, et al. Different determinants of improvement of early and late systolic mitral regurgitation contributed after cardiac resynchronization therapy. J Am Soc Echocardiogr 2010;23:1160–7.

Toff WD, Cann AJ, Skehan JD. Single-chamber versus dual-chamber pacing for high-grade atrioventricular block. N Engl J Med 2005;353:145–55.

Brenyo A, Goldenberg I, Barsheeshet A. The downside of right ventricular apical pacing. Indian Pacing Electrophysiol J 2012;12:102–13.

Barsheeshet A, Moss AJ, McNitt S, Jons C, Glisson M, Klein HU, et al. Long-term implications of cumulative right ventricular pacing among patients with an implantable cardioverter-defibrillator. Heart Rhythm 2011;8:212–8.

Hayes JJ, Sharma AD, Love JC, Herre JM, Leonen AO, Kudenchuk PJ. Abnormal conduction increases risk of adverse outcomes from right ventricular pacing. J Am Coll Cardiol 2006;48:1628–33.

Ghani A, Delnopy PF, Ottervanger JP, Ramdat Misier AR, Smit JJ, Elvan A. Assessment of left ventricular dyssynchrony in pace-induced left bundle branch block compared with intrinsic left bundle branch block. Europace 2011;13:1504–7.

Brigole M, Gianfranchi L, Menozzi C, Alboni P, Musso G, Bongiorni MG, et al. Assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation: a randomized controlled study. Circulation 1997;96:2617–24.

Andersen HR, Nielsen JC, Thomsen PE, Thuesen L, Mortensen PT, Cederlund T, et al. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet 1997;350:1210–6.

Prinzen FW, Peschar M. Relation between the pacing induced sequence of activation and left ventricular pump function in animals. Pacing Clin Electrophysiol 2002;25:484–98.

Vassallo JA, Cassidy DM, Miller JM, Buxton AE, Marchlinski FE, Josephson ME. Left ventricular endocardial activation during right ventricular pacing: effect of underlying heart disease. J Am Coll Cardiol 1986;7:1228–33.

Auricchio A, Salo RW. Acute hemodynamic improvement by pacing in patients with severe congestive heart failure. Pacing Clin Electrophysiol 1997;20:313–24.

Bordachar P, Lafitte S, Reuter S, Garrigue S, Sanders P, Roudaut R, et al. Biventricular pacing and left ventricular pacing in heart failure: similar hemodynamic improvement despite marked electromechanical differences. J Cardiovasc Electrophysiol 2004;15:1342–7.

Varma N, Jia P, Ramanathan C, Rudy Y. RV electrical activation in heart failure during right, left, and biventricular pacing. JACC Cardiovasc Imaging 2010;3:567–75.

Birnie D, Lemke B, Aonuma K, Krum H, Lee KL, Gasparini M, et al. Clinical outcomes with synchronized left ventricular pacing: analysis of the adaptive CRT trial. Heart Rhythm 2013;10:1368–74.

Vernooy K, van Deursen CJ, Strik M, Prinzen FW. Strategies to improve cardiac resynchronization therapy. Nat Rev Cardiol 2014 Aug;11(8):481–93.

Asirvatham SJ. Cardiac resynchronization: is electrical synchrony relevant? J Cardiovasc Electrophysiol 2007;18:1028–31.

Saksena S. Bundle branch block and cardiac resynchronization therapy: do we need to look further before we leap? J Interv Card Electrophysiol 2003;8:163–4.

Sipahi I, Fang JC. CRT should be reserved for a QRS duration >150 ms: pro. Circ Arrhythm Electrophysiol 2013;6:436–42.

Pitzaftis MV, Iacoviello M, Romito R, Massari F, Rizzone B, Luzzi G, et al. Cardiac resynchronization therapy tailored by echocardiographic evaluation of ventricular asynchrony. J Am Coll Cardiol 2002;40:1615–22.

Bax JJ, Marwick TH, Molhoek SG, Bleeker GB, van Erven L, van Deursen CJ, et al. Long-term implications of cumulative right ventricular reverse remodeling after cardiac resynchronization therapy. Heart Rhythm 2013;10:979–87.

Goldenberg J, Kutyifa V, Klein HU, Cannom DS, Brown MW, Dan A, et al. Survival with cardiac-resynchronization...
therapy in mild heart failure. N Engl J Med 2014 May 1;370(18):1694–701.

[60] Ruschitzka F, Abraham WT, Singh JP, Bax JJ, Borger JS, Brugada J, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med 2013;369:1395–405.

[61] Wyman BT, Hunter WC, Prinzen FW, McVeigh ER. Mapping propagation of mechanical activation in the paced heart with MRI tagging. Am J Physiol 1999;276:H881–91.

[62] Russell K, Simmeth OA, Gjedal O, Qvigstad E, Norseng PA, Sjaastad I, et al. Mechanism of prolonged electromechanical delay in late activated myocardium during left bundle branch block. Am J Physiol Heart Circ Physiol 2011;301:H2334–43.

[63] Herweg B, Ali R, Ilercil A, Madramootoo C, Cuto R, Weston MW, et al. Site-specific differences in latency intervals during biventricular pacing: impact on paced QRS morphology and echo-optimized V-V interval. Pacing Clin Electrophysiol 2010;33:1382–91.

[64] Barold SS, Herweg B, Ali R, Ilercil A, Madramootoo C, Cutro R, Russell K, Smiseth OA, Gjesdal O, Qvigstad E, et al. Usefulness of the 12-lead electrocardiogram in the follow-up of patients with cardiac resynchronization devices. Part II Cardiol J 2011;18:610–8.

[65] Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Barold SS, Herweg B. The effect of cardiac resynchronization devices on symptoms and functional status in patients with intraventricular dyssynchrony. J Am Coll Cardiol 2007;99:657–63.

[66] Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845–53.

[67] Bleeker GB, Kaandorp TA, Lamb HJ, Boersma E, Steendijk P, White JA, Yee R, Yuan X, Krahn A, Skanes A, Parker M, et al. Pacemaker induced mitral regurgitation regression by slight modification of the right ventricular pacing site. Circ J 2008;72:1465–70.

[68] Almlof J, Jansen AH, Bratteby T, van Dijk JF, Post JC, van den Bosch FC, et al. The influence of myocardial scar and dyssynchrony on reverse remodeling in cardiac resynchronization therapy. Eur J Heart J 2008;29:483–8.

[69] Dendy KF, Powell BD, Cha YM, Espinosa RE, Friedman PA, Rea RF, et al. Anodal stimulation: an unrecognized cause of nonresponders to cardiac resynchronization therapy. Indian Pacing Electrophysiol J 2011;11:64–72.

[70] Tamborero D, Mont L, Alanis R, Berreauza A, Tolosa-JM, Sitges M, et al. Anodal capture in cardiac resynchronization therapy implications for device programming. Pacing Clin Electrophysiol 2006;29:940–5.

[71] Lloyd MS, Heeke S, Lerakis S, Langberg JJ. Reverse polarity pacing: the hemodynamic benefit of anodal currents at lead tips for cardiac resynchronization therapy. J Cardiovasc Electrophysiol 2007;18:1167–71.

[72] Ranjan R, Chiamvimonvat N, Thakor NV, Tomaselii GF, Marban E. Mechanism of anode break stimulation in the heart. Biophys J 1850-1863;1998:74.
Effect of left bundle branch pacing therapy on mitral regurgitation as demonstrated in a community: the emerging role of mitral regurgitation. J Am Coll Cardiol 2007;50:2071–7.

Trichon BH, Felker GM, Shaw LK, Cabell CH, O’Connor CM. Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. Am J Cardiol 2003;91:538–43.

Bursi F, Enriquez-Sarano M, Nkomo VT, Jacobsen SJ, Weston SA, Mevenrer RA, et al. Heart failure and death after myocardial infarction in the community: the emerging role of mitral regurgitation. Circulation 2005;111:295–301.

Topilsky Y, Vaturi O, Watanabe N, Bichara V, Nkomo VT, Bursi F, Enriquez-Sarano M, Nkomo VT, Jacobsen SJ, Koide Y, et al. The hemodynamic benefit of biventricular pacing therapy on dysynchrony and mitral regurgitation. J Am Soc Echocardiogr 2007;20:54.

Pierard LA, et al. Acute effects of initiation and withdrawal of cardiac resynchronization therapy on papillary muscle dysfunction and heart failure. Am J Cardiol 2003;91:538–43.

Connor CM, Deshmukh PM, Romanyshyn M. Direct His-bundle pacing: a technique for stable His-bundle recording and pacing: beyond the transvenous right ventricular pacing site: long-term follow-up. Pacing Clin Electrophysiol 1995;18:1894.

Piccinino C, Plebani L, et al. Prevention of ventricular arrhythmia by cardiac resynchronization therapy in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2010;105:1426.

Kypa A, Steinwender C, Cammler J, Leisch F, Hofmann R. Long-term outcomes in patients with atrioventricular block undergoing septal ventricular lead implantation compared with standard apical pacing. Europace 2008;10:574–9.

Vanero G, Vidal JL, Fernandez Banizi P, Banina Aguerre D, Viana P, Tejada J. Medium- and long-term survival after pacemaker implant: improved survival with right ventricular outflow tract pacing. J Interv Card Electrophysiol 2008;21:195–201.

Deshmukh P, Casavant DA, Romanyshyn M, Anderson K. Permanent, direct His-bundle pacing: a novel approach to cardiac pacing in patients with normal His-Purkinje activation. Circulation 2000;101:869–77.

Kapa S, Bruce CJ, Friedman PA, Asirvatham SJ. Advances in cardiac pacing: beyond the transvenous right ventricular apical lead. Cardiovasc Ther 2010;28:369–79.

Giudici MC, Thornburg GA, Buck DL, Coyne EP, Walton MC, Paul DL, et al. Comparison of right ventricular outflow tract and apical lead permanent pacing on cardiac output. Am J Cardiol 1997;79:209–12.

Victor F, Leclercq C, Mabo P, Pavin D, Deviller A, de Place C, Kapa S, Bruce CJ, Friedman PA, Asirvatham SJ, et al. Comparison of apical and outflow tract pacing in patients with normal His-Purkinje activation. Circulation 2008;101:869–77.

Deshmukh P, Casavant DA, Romanyshyn M, Anderson K. Permanent, direct His-bundle pacing: a novel approach to cardiac pacing in patients with normal His-Purkinje activation. Circulation 2000;101:869–77.

Kapa S, Bruce CJ, Friedman PA, Asirvatham SJ. Advances in cardiac pacing: beyond the transvenous right ventricular apical lead. Cardiovasc Ther 2010;28:369–79.

Barin ES, Jones SM, Ward DE, Camm AJ, Nathan AW. The right ventricular outflow tract as an alternative permanent pacing site: long-term follow-up. Pacing Clin Electrophysiol 1991;4:13–6.

Bursi F, Enriquez-Sarano M, Nkomo VT, Jacobsen SJ, Weston SA, Mevenrer RA, et al. Heart failure and death after myocardial infarction in the community: the emerging role of mitral regurgitation. Circulation 2005;111:295–301.

Topilsky Y, Vaturi O, Watanabe N, Bichara V, Nkomo VT, Michlelena H, et al. Real-time 3-dimensional dynamics of functional mitral regurgitation: a prospective quantitative and mechanistic study. J Am Heart Assoc 2013;2:e000339.

Xiao HB, Lown J, Gibson DG. Effect of left bundle branch block on diastolic function in dilated cardiomyopathy. Br Heart J 1991;66:443–7.

Vinereanu D, Turner MS, Bleasdale RA, Mumford CE, Cinteza M, Frenneaux MP, et al. Mechanisms of reduction of mitral regurgitation by cardiac resynchronization therapy. J Am Soc Echocardiogr 2007:20:54–62.

Solis J, McCarty D, Levine RA, Handschumacher MD, Fernandez-Friera L, Chen-Tournoux A, et al. Mechanism of decrease in mitral regurgitation after cardiac resynchronization therapy: optimization of the force-balance relationship. Circ Cardiovasc Imaging 2009;2:444–50.

Breithardt OA, Sinha AM, Schwammenthal E, Bidaoui N, Markus KU, Franke A, et al. Acute effects of cardiac resynchronization therapy on functional mitral regurgitation in advanced systolic heart failure. J Am Coll Cardiol 2003;41:765–70.

Matsumoto K, Tanaka H, Okajima K, Hayashi T, Kajiya T, Kawai H, et al. Relation between left ventricular morphology and reduction in functional mitral regurgitation by cardiac resynchronization therapy in patients with idiopathic dilated cardiomyopathy. J Am J Cardiol 2011;108:1327–34.

Desimone CV, Nkomo VT, Desimone DC, Keenan LR, Enriquez-Sarano M, Asirvatham SJ. An approach to the stepwise management of severe mitral regurgitation with optimal cardiac pacemaker function. Indian Pacing and Electrophysiol J 2014;14:75–8.

Dong YX, Powell BD, Asirvatham SJ, Friedman PA, Rea RF, Webster TL, et al. Left ventricular lead position for cardiac resynchronization: a comprehensive cineangiographic, echocardiographic, clinical, and survival analysis. Europace 2012;14:1139–47.

Brady PA, Hammill SC. Ventricular-based pacing: one site fits all? J Cardiovasc Electrophysiol 2003;14:1187–8.

Stambler BS, Ellenbogen K, Zang X, Porter TR, Xie F, Malik K, et al. Right ventricular outflow versus apical pacing in pacemaker patients with congestive heart failure and atrial fibrillation. J Cardiovasc Electrophysiol 2003;14:1180–6.

Victor F, Mahida Y, Mansour H, Pavin D, Kabalu G, de Place C, et al. A randomized comparison of permanent septal versus apical right ventricular pacing: short-term results. J Cardiovasc Electrophysiol 2006;17:238–42.
[124] Reddy VY, Knops RE, Sperzel J, Miller MA, Petru J, Simon J, et al. Permanent leadless cardiac pacing: results of the leadless trial. Circulation 2014 Apr 8;129(14):1466–71.

[125] Leclercq C, Gadler F, Kranig W, Ellery S, Gras D, Lazarus A, et al. A randomized comparison of triple-site versus dual-site ventricular stimulation in patients with congestive heart failure. J Am Coll Cardiol 2008;51:1455–62.

[126] Thibault B, Dubuc M, Khairy P, Guerra PG, Macle L, Rivard L, et al. Acute haemodynamic comparison of multisite and biventricular pacing with a quadripolar left ventricular lead. Europace 2013;15:984–91.

[127] Asirvatham SJ, Bruce CJ, Danielsen A, Johnson SB, Okumura Y, Kathmann E, et al. Intramyocardial pacing and sensing for the enhancement of cardiac stimulation and sensing specificity. Pacing Clin Electrophysiol 2007;30:748–54.